NASDAQ: RXRXRecursion Pharmaceuticals Inc Stock
$5.41-0.09 (-1.64%)
Updated Apr 21, 2025
RXRX Price
$5.41
Fair Value Price
N/A
Market Cap
$2.17B
52 Week Low
$3.79
52 Week High
$12.36
P/E
-3.2x
P/B
2.1x
P/S
31.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$58.84M
Earnings
-$463.66M
Gross Margin
23.1%
Operating Margin
-789.93%
Profit Margin
-788%
Debt to Equity
0.4
Operating Cash Flow
-$359M
Beta
2.24
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RXRX Overview
Recursion Pharmaceuticals Incorporated is a clinical-stage biotechnology company that integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is developing REC-994, which is in Phase IIa clinical trials to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trials to treat GM2 gangliosidosis. Recursion Pharmaceuticals was incorporated in 2013 and is headquartered in Salt Lake City, UT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RXRX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RXRX
Ranked#460 of 462
Ranked#460 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important RXRX news, forecast changes, insider trades & much more!
RXRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RXRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RXRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RXRX is good value based on its book value relative to its share price (2.1x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
RXRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RXRX due diligence checks available for Premium users.
Valuation
RXRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.2x
Industry
-184.27x
Market
27.14x
RXRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.1x
Industry
4.04x
RXRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RXRX's financial health
Profit margin
Revenue
$4.5M
Net Income
-$178.9M
Profit Margin
-3,935.5%
RXRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RXRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$413.8M
Debt to equity
0.4
RXRX's short-term assets ($714.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RXRX's short-term assets ($714.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RXRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RXRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$115.4M
Investing
$275.5M
Financing
$10.6M
RXRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RXRX vs Biotech Stocks
Recursion Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.